Suggestions
Daniel Haders II, Ph.D.
Healthcare Operator, Investor, BoD Member
Daniel Haders II, Ph.D. is a prominent healthcare entrepreneur, advisor, and investor with over two decades of experience in the industry. His LinkedIn username is daniel-hadersphd.2
Professional Background
Dr. Haders has a diverse and impressive background in healthcare and biotech:
Education and Early Career:
- Studied Biomedical Engineering & Materials Science and Engineering at Columbia University
- Completed a Ph.D. in Biomedical Engineering & Materials Science and Engineering at Rutgers University
- Was a Recognized Visiting Graduate Student in Materials Science and Engineering at The University of Oxford
Current Roles:
- Co-Founder and CEO of Model Medicines, a preclinical stage AI/ML Drug Discovery company1
- Operating Partner at Sway Ventures, a US-based venture capital firm
- Faculty Member and Advisory Committee Member of the UCSD Digital Health Certificate Program
- Board Observer at AppliedVR, a VR digital therapeutic company3
Previous Positions:
- Managing Director of Digital Health at Nex Cubed
- Founder, President & CEO at Sanar Biosciences
- Research Engineer at IBM
Achievements and Recognition
Dr. Haders has made significant contributions to the healthcare industry:
- Launched the Nex Cubed Digital Health Accelerator, named one of the "Top Ten Global Digital Health Accelerators"
- Co-founded Model Medicines, which is innovating in AI-driven drug discovery1
- Developed the AI Pharma Code, which is poised to become a new industry standard for assessing AI-driven drug discovery capabilities1
Personal Life
Dr. Haders is married to a physician and is a father to three children.34
While the query specifically asks about Dr. Haders' role as a Member of the Board of Directors at Consano Biologics, this information is not provided in the given search results. The available information focuses on his other roles and achievements in the healthcare and biotech industries.
Highlights
Model Medicines is honored to be featured in a recent article about the AI Drug Discovery industry by Microsoft News, highlighting the few companies that have achieved both platform and therapeutic success. To read the full article, click here: https://lnkd.in/gPkxkyGi
#ai #aidrugdiscovery #pharmaceuticals #oncology #cancer #infectiousdisease
Launa Aspeslet Davey Smith, MD, MAS, FACP, FIDSA Sean Russell Tyler Umansky Virgil Woods Navya Tippananapalya Ramesh Patrick ONeill Lani O. Bret Awbrey Thalia Gietzen Tushar Menon, PhD David Garvey 8VC Alex Moore Seth L. Irving Investors Jeremy Abelson Andrew Kalmar Christopher Chism Jeffrey Friedman Thermopolis Partners LLC Philip Treick Clayton E. Hartman Nex Cubed Marlon Evans Kip Quackenbush ParticleX Kevin Whalen Delilah Panio Kristina M. Herbert, Ph.D. Greg Goldner Stephanie Walek Nick Phillips Ken Denman Greg White Fan Zhang, PhD Dwight French Cameron Parow
Model Medicines, is excited to propose a new standard for assessing the capabilities and potential of AI drug discovery companies: The AI Pharma Code. This set of criteria aims to differentiate the most promising players in the field and provide a comprehensive measure of their ability to revolutionize the drug discovery process.
The AI Pharma Code consists of the following criteria:
- New Biology/Target Discovery
- New Chemical Entities
- Zero-Shot Hit Rates >30% at <20μM
- Tanimoto Scores <0.5
- Pipeline Across Biology & Disease
- Preclinical POC in Gold Standard Animal Model
At Model Medicines, we are proud to adhere to The AI Pharma Code. Our proprietary GALILEO™ platform has enabled us to identify novel targets, such as the RdRp Thumb-1 site, and generate NCEs with an unprecedented 66.7% hit rate for pan-antiviral activity at a concentration well below 20μM in zero-shot learning experiments. Our AI-generated compounds have an average Tanimoto score of 0.32, showcasing their structural novelty and diversity. We have a broad pipeline spanning multiple therapeutic areas of oncology, virology, weight disorders, and rare diseases. Our lead asset, MDL-001, has demonstrated preclinical proof of concept in a gold-standard animal model.
We believe that The AI Pharma Code sets a new bar for excellence in AI drug discovery, and we encourage our peers, partners, and investors to embrace this standard. By holding ourselves accountable to these rigorous criteria, we can accelerate the development of transformative therapies and realize the full potential of AI in revolutionizing the pharmaceutical industry.
Join us in this exciting journey as we redefine the future of drug discovery and development! 🚀
#TheAIPharmaCode #AIDrugDiscovery
Sean Russell Tyler Umansky Virgil Woods Navya Tippananapalya Ramesh Patrick ONeill Lani O. Bret Awbrey Thalia Gietzen Davey Smith, MD, MAS, FACP, FIDSA Tushar Menon, PhD David Garvey Launa Aspeslet 8VC Alex Moore Nex Cubed Kip Quackenbush Marlon Evans ParticleX Jeffrey Friedman Thermopolis Partners LLC Philip Treick Clayton E. Hartman Kevin Whalen Irving Investors Jeremy Abelson Andrew Kalmar Christopher Chism Delilah Panio Kristina M. Herbert, Ph.D. Greg Goldner Stephanie Walek Nick Phillips Paul Ostrowski Tim Lugo Greg White Fan Zhang, PhD Oivin Guicherit Stacie Calad-Thomson Ken Denman
